Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the Licensing Agreement, OncoVerity will optimize JNJ-74494550 (cusatuzumab), a first-in-class anti-CD70 antibody, in acute myeloid leukemia (AML) and explore its application in other cancers.
Lead Product(s): Cusatuzumab,Azacitidine
Therapeutic Area: Oncology Product Name: JNJ-74494550
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Argenx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 27, 2023
Details:
The net proceeds will be used for the continued development JNJ-74494550 (cusatuzumab), a first-in-class anti-CD70 antibody for the treatment of acute myeloid leukemia (AML).
Lead Product(s): Cusatuzumab,Azacitidine
Therapeutic Area: Oncology Product Name: JNJ-74494550
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Argenx
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 27, 2023